For a patient with dilated cardiomyopathy, which pathophysiological change is primarily expected?

Dilated cardiomyopathy is characterized by extensive myocardial remodeling, specifically the eccentric expansion of the cardiac chambers. This structural degradation involves the stretching of myocytes, leading to impaired contractile force and a significant reduction in the ejection fraction, ultimately resulting in progressive systolic heart failure. Rationale: A. The hallmark of this condition is the progressive enlargement of the cardiac chambers. This ventricular dilation increases the end-diastolic volume while decreasing the thickness of the ventricular wall, significantly compromising systolic function and leading to stasis of blood within the heart, which increases thromboembolism risk. B. This valvular pathology involves the narrowing of the mitral valve orifice. Mitral stenosis is typically a sequela of rheumatic heart disease or calcification and is not the primary pathophysiological driver of dilated cardiomyopathy, which focuses on ventricular architecture rather than primary valvular obstruction or restricted inflow. C. This change involves the thickening of the ventricular walls. Ventricular hypertrophy is more indicative of hypertrophic cardiomyopathy or chronic hypertension, where the heart muscle becomes abnormally thick; in contrast, dilated cardiomyopathy presents with wall thinning due to the stretching and enlargement of the ventricles. D. This is a congenital structural abnormality in the cardiac septum. An atrial septal defect involves an opening between the left and right atria, leading to shunting, whereas dilated cardiomyopathy is an acquired or genetic disease of the heart muscle itself affecting the ventricular pumping capacity.